There are several new therapeutic options, such as immune checkpoint blockade, but most of these therapeutic strategies do not target the tumor cell itself but cells of the tumor microenvironment, primarily infiltrating CD8+ cytotoxic T cells, γδ T cells and T helper 1 cells. Here, CD8A is linked to neoplasm.